By Sherri Oslick --
About Court Report: Each week we will report briefly
on recently filed biotech and pharma patent cases. A few interesting cases will be selected for
periodic monitoring, providing our readers with an opportunity to follow the
progress of these cases.
Novartis Corp. et. a. v. Lupin Ltd. et al.
2:06-cv-05954; filed December 12, 2006 in the District
Court of New Jersey
Infringement of U.S. Patent No. 6,162,802
("Synergistic Combination Therapy Using Benazepril and Amlodipine for the
Treatment of Cardiovascular Disorders and Compositions Therefor," issued
December 19, 2000) following a paragraph IV certification as part of Lupin's
filing of an ANDA to manufacture a generic version of Novartis' Lotrel®
(amlodipine besylate/benazepril hydrochloride, used to treat
hypertension). View the complaint here.
Ortho-McNeil Pharmaceutical, Inc. v. Barr Laboratories,
Inc. et. al.
3:06-cv-06012; filed December 15, 2006 in the District
Court of New Jersey
Infringement of U.S. Patent No. 7,125,560
("Pharmaceutical Composition of Topiramate," issued October 24, 2006)
following a paragraph IV certification as part of Barr's filing of an ANDA to
manufacture a generic version of Ortho-McNeil's Topamax® (topiramate used to
treat migraines and epilepsy). View the
complaint here.
Reliant Pharmaceuticals, Inc. v. Par Pharmaceutical, Inc.
1:06-cv-00774 ; filed December 19, 2006 in the District
Court of Delaware
Infringement of U.S. Patent No. 5,681,588 ("Delayed
Release Microtablet of ß-phenylpropiophenone Derivatives," issued October
28, 1997) following a paragraph IV certification as part of Par's filing of an
ANDA to manufacture a generic version of Reliants's Rythmol® SR (propaphenone
hydrochloride extended release; used to prolong the time to recurrence of
symptomatic atrial fibrillation in patients without structural heart
disease). View the complaint here.
Comments